lysosomal disease

ly·so·so·mal dis·ease

a disease due to inadequate functioning of a lysosomal enzyme; most such diseases are associated with a storage disease.

ly·so·so·mal dis·ease

(lī'sō-sō'măl di-zēz')
A disease due to inadequate functioning of a lysosomal enzyme; most such diseases are associated with a storage disease.

ly·so·so·mal dis·ease

(lī'sō-sō'măl di-zēz')
Disorder due to inadequate functioning of a lysosomal enzyme.
Mentioned in ?
References in periodicals archive ?
Dr Whitley is a key opinion leader in the field of lysosomal diseases, founding Course director for WORLDSymposium, and Principal Investigator for the global Lysosomal Disease Network.
Infantile neuronal ceroid lipofuscinosis (INCL) is a severe lysosomal disease caused by mutations in the CLN1 gene, which encodes the soluble lysosomal enzyme Palmitoyl- Protein-Thioesterase-1 (PPT1) and result in osmiophilic granules accumulating in lysosomes and leading to neuroinflammation, neurodegeneration and death.
Hunter syndrome (mucopolysaccharidosis type II (MPS II)) is a lysosomal disease characterized by deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S).
[G.sub.M1]-gagliosidosis is a relatively rare lysosomal disease, presenting clinically with progressive neurological deterioration mainly in infancy and childhood with various somatic manifestations.
Citation: "Myeloid/Microglial Driven Autologous Hematopoietic Stem Cell Gene Therapy Corrects a Neuronopathic Lysosomal Disease"; Ana Sergijenko et al.; Molecular Therapy, 2013; DOI: 10.1038/mt.2013.141
Genzyme said on Friday that it has presented positive new data from its Phase 3 ENGAGE and ENCORE studies of its investigational oral therapy eliglustat tartrate for Gaucher disease type 1 at the 9th Annual Lysosomal Disease Network WORLD Symposium in Orlando, Fla.
In February 2010, the company announced Phase III data at the Lysosomal Disease Network's WORLD symposium.
[Otospongiosis, a cellular and enzymatic lysosomal disease. Cyto-clinical correlation].
M2 PHARMA-February 10, 2012-Synageva BioPharma presents positive interim data at eighth annual Lysosomal Disease Network (LDN) World Symposium(C)2012 M2 COMMUNICATIONS
Biopharmaceutical company Amicus Therapeutics (Nasdaq:FOLD) said on Thursday that the preclinical studies of its AT3375 for Gaucher disease were presented at the eighth Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD).
Protalix BioTherapeutics Inc (NYSE:PLX) (AMEX:PLX) (TASE:PLX) announced on Thursday that new clinical data on taliglucerase alfa will be presented at the 8th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2012 being held on 8-10 February in San Diego.
These two-year results were presented at the Lysosomal Disease Network WORLD Symposium earlier this year, Genzyme added.

Full browser ?